These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214 [TBL] [Abstract][Full Text] [Related]
6. Chemotherapy and targeted therapy in the management of cervical cancer. Kumar L; Harish P; Malik PS; Khurana S Curr Probl Cancer; 2018; 42(2):120-128. PubMed ID: 29530393 [TBL] [Abstract][Full Text] [Related]
7. Overview of resistance to systemic therapy in patients with breast cancer. Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer. Eskander RN; Tewari KS Clin Ther; 2015 Jan; 37(1):20-38. PubMed ID: 25592089 [TBL] [Abstract][Full Text] [Related]
9. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. Monk BJ; Tewari KS; Koh WJ J Clin Oncol; 2007 Jul; 25(20):2952-65. PubMed ID: 17617527 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy in cervical cancer patients with high risk factors. Park TK Yonsei Med J; 1997 Oct; 38(5):255-60. PubMed ID: 9409188 [TBL] [Abstract][Full Text] [Related]
11. Sorafenib in lung cancer: clinical developments and future directions. Blumenschein G J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S124-7. PubMed ID: 18520294 [TBL] [Abstract][Full Text] [Related]
12. Anti-vascular endothelial growth factor therapy in the era of personalized medicine. Féliz LR; Tsimberidou AM Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481 [TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy. Rossi A; Maione P; Sacco PC; Ambrosio R; Falanga M; Gridelli C Curr Drug Targets; 2010 Jul; 11(7):865-8784. PubMed ID: 20412044 [TBL] [Abstract][Full Text] [Related]
14. Integrating Chemotherapy in the Management of Cervical Cancer: A Critical Appraisal. Kumar L; Gupta S Oncology; 2016; 91 Suppl 1():8-17. PubMed ID: 27464068 [TBL] [Abstract][Full Text] [Related]
15. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835 [TBL] [Abstract][Full Text] [Related]
16. Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments. Lheureux S; Oza AM Eur J Cancer; 2016 May; 59():99-108. PubMed ID: 27017291 [TBL] [Abstract][Full Text] [Related]
17. New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy. Tewari KS; Monk BJ Clin Cancer Res; 2014 Nov; 20(21):5349-58. PubMed ID: 25104084 [TBL] [Abstract][Full Text] [Related]
18. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. Tewari KS; Monk BJ Semin Oncol; 2009 Apr; 36(2):170-80. PubMed ID: 19332251 [TBL] [Abstract][Full Text] [Related]
19. Antiangiogenesis, anti-VEGF(R) and outlook. Petersen I Recent Results Cancer Res; 2007; 176():189-99. PubMed ID: 17607926 [TBL] [Abstract][Full Text] [Related]
20. Locally advanced cervical cancer: what is the standard of care? Al-Mansour Z; Verschraegen C Curr Opin Oncol; 2010 Sep; 22(5):503-12. PubMed ID: 20473164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]